BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 32553712)

  • 1. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases.
    Yu Y; Su X; Qin Q; Hou Y; Zhang X; Zhang H; Jia M; Chen Y
    Pharmacol Res; 2020 Sep; 159():105009. PubMed ID: 32553712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Cardiovascular Diseases.
    Li R; Huang W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review on decoding the roles of YAP/TAZ signaling pathway in cardiovascular diseases: Bridging molecular mechanisms to therapeutic insights.
    Zhang Y; Ren Y; Li X; Li M; Fu M; Zhou W; Yu Y; Xiong Y
    Int J Biol Macromol; 2024 Jun; 271(Pt 2):132473. PubMed ID: 38795886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 5. Thromboxane A2 Activates YAP/TAZ Protein to Induce Vascular Smooth Muscle Cell Proliferation and Migration.
    Feng X; Liu P; Zhou X; Li MT; Li FL; Wang Z; Meng Z; Sun YP; Yu Y; Xiong Y; Yuan HX; Guan KL
    J Biol Chem; 2016 Sep; 291(36):18947-58. PubMed ID: 27382053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Connective Tissue Growth Factor Expression in Adult Retinal Pigment Epithelial-19 Cells by Blocking Yes-Associated Protein/Transcriptional Coactivator with PDZ-Binding Motif Activity.
    Murakami Y; Imaizumi T; Hashizume K; Tezuka Y; Oku Y; Nishiya N; Sanbe A; Kurosaka D
    J Ocul Pharmacol Ther; 2024 May; 40(4):246-252. PubMed ID: 38517736
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
    He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
    Elife; 2021 Aug; 10():. PubMed ID: 34463254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
    Pobbati AV; Hong W
    Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP/TAZ signaling.
    Wu P; Liu Z; Zhao T; Xia F; Gong L; Zheng Z; Chen Z; Yang T; Duan Q
    Biochem Biophys Res Commun; 2019 May; 512(4):736-741. PubMed ID: 30926167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
    Konishi T; Schuster RM; Lentsch AB
    Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G471-G482. PubMed ID: 29351389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.
    Dieffenbach PB; Haeger CM; Coronata AMF; Choi KM; Varelas X; Tschumperlin DJ; Fredenburgh LE
    Am J Physiol Lung Cell Mol Physiol; 2017 Sep; 313(3):L628-L647. PubMed ID: 28642262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
    Rozengurt E; Eibl G
    World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.